Clinical Trials Logo

Clinical Trial Summary

This is a single-arm, open, multicenter, phase 2 study to evaluate the efficacy, safety and pharmacokinetics of HYLM-122 in combination with cytarabine in Chinese subjects with FLT3 positive relapsed or refractory acute myeloid leukemia.


Clinical Trial Description

This study will have two phases. Phase 1: the escalation phase is to establish the recommended phase 2 dose (RP2D) of HYML-122 given in combination with cytarabine. Phase 2: the extension phase study will treat patients with FLT3 positive relapsed or refractory AML with HYML-122 in combination with cytarabine at the RP2D, and further evaluate efficacy and safety. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05241093
Study type Interventional
Source Tarapeutics Science Inc.
Contact Yang Shu, MD. BS.
Phone +8613918983465
Email shuyang@tarapeutics.com
Status Recruiting
Phase Phase 2
Start date March 29, 2022
Completion date June 30, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05241106 - A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 2
Terminated NCT04113616 - An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) Phase 1/Phase 2
Recruiting NCT02074839 - Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation Phase 1
Terminated NCT05345938 - A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia Phase 1/Phase 2
Terminated NCT03218683 - Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies. Phase 1